Abstract
Median ages at CRC diagnosis and death are 67 and 72 years, respectively. Older patients (pts) are underrepresented in clinical trials and often undertreated in daily practice. Here, we report the impact of age on effectiveness, quality of life (QoL) and safety of aflibercept plus FOLFIRI in mCRC pts previously treated with an oxaliplatin-containing regimen.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call